(S (NP (NP (JJ Recent) (NNS advances)) (PP (IN in) (NP (NML (JJ medical) (NN imaging)) (NNS techniques)))) (VP (VBP have) (VP (VBN led) (PP (IN to) (NP (JJ significant) (NNS improvements))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NN prostate) (NN cancer))))) (PRN (-LRB- -LRB-) (NP (NN PCa)) (-RRB- -RRB-)))) (. .))
(S (PP (IN In) (ADJP (JJ particular))) (, ,) (NP (JJ multi-parametric) (NN MRI) (PRN (-LRB- -LRB-) (NP (NN mp) (HYPH -) (NN MRI)) (-RRB- -RRB-))) (VP (VBZ continues) (S (VP (TO to) (VP (VB gain) (NP (JJ clinical) (NN acceptance)) (PP (IN as) (NP (NP (DT the) (NML (JJ preferred) (NN imaging)) (NN technique)) (PP (IN for) (NP (NP (JJ non-invasive) (NN detection) (CC and) (NN grading)) (PP (IN of) (NP (NN PCa))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NP (DT the) (ADJP (NP (NN machine) (NN learning)) (HYPH -) (VBN based)) (NN diagnosis) (NNS systems)) (PP (IN for) (NP (NN PCa)))) (VP (VBP are) (ADVP (RB often)) (VP (VBN constrained) (PP (IN by) (NP (DT the) (JJ limited) (NN access))) (PP (IN to) (NP (NP (JJ accurate) (NN lesion) (NN ground) (NN truth) (NNS annotations)) (PP (IN for) (NP (NN training))))))) (. .))
(S (NP (NP (DT The) (NN performance)) (PP (IN of) (NP (DT the) (NML (NN machine) (NN learning)) (NN system)))) (VP (VBZ is) (ADJP (RB highly) (JJ dependable) (PP (IN on) (NP (NP (DT both) (NN quality) (CC and) (NN quantity)) (PP (IN of) (NP (NP (NN lesion) (NNS annotations)) (VP (VBN associated) (PP (IN with) (NP (JJ histopathologic) (NNS findings))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ limited) (NN scalability)) (CC and) (NP (JJ clinical) (NN validation))))))))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (DT the) (NN baseline) (NN MRI) (NN model)) (PP (IN to) (S (S (ADVP (RB alternatively)) (VP (VB learn) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NN mp) (HYPH -) (NN MRI)))))) (VP (VBG using) (NP (NP (ADJP (NP (NN radiology)) (HYPH -) (VBN confirmed)) (JJ negative) (NN MRI) (NNS cases)) (PP (IN via) (NP (ADJP (RB weakly) (JJ supervised)) (NN learning)))))))) (. .))
(S (SBAR (IN Since) (S (NP (NN PCa) (NNS lesions)) (VP (VBP are) (ADJP (ADJP (NN case) (HYPH -) (JJ specific)) (CC and) (ADJP (RB highly) (JJ heterogeneous)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN assumed) (S (VP (TO to) (VP (VB be) (VP (VBG challenging) (PP (IN to) (NP (NML (S (VP (VB synthesize) (NP (NN PCa) (NNS lesions)) (S (VP (VBG using) (NP (DT the) (NN baseline) (NN MRI))))))) (NN model))))))) (, ,) (SBAR (IN while) (S (NP (PRP it)) (VP (MD would) (VP (VB be) (ADJP (ADJP (RB relatively) (JJR easier)) (S (VP (TO to) (VP (VB synthesize) (NP (DT the) (JJ normal) (NN appearance)) (PP (IN in) (NP (NN mp) (HYPH -) (NN MRI))))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB then)) (VP (VBP utilize) (NP (DT the) (NN baseline) (NN MRI) (NN model)) (PP (IN to) (VP (VB infer) (NP (NP (DT the) (JJ pixel-wise) (NN suspiciousness)) (PP (IN of) (NP (NN PCa)))) (PP (IN by) (S (VP (VBG comparing) (NP (NP (DT the) (ADJP (JJ original) (CC and) (VBN synthesized)) (NN MRI)) (PP (IN with) (NP (NML (CD two) (NN distance)) (NNS functions)))))))))) (. .))
(S (NP (PRP We)) (VP (VBD trained) (CC and) (VBD validated) (NP (DT the) (NN baseline) (NN MRI) (NN model)) (S (VP (VBG using) (NP (CD 1,145) (JJ negative) (NN prostate) (NN mp) (HYPH -) (NN MRI) (NNS scans))))) (. .))
(S (PP (IN For) (NP (NN evaluation))) (, ,) (NP (PRP we)) (VP (VBD used) (VP (VBN separated) (NP (NML (CD 232) (NN mp)) (HYPH -) (NN MRI) (NNS scans)) (, ,) (S (VP (VBG consisting) (PP (IN of) (NP (DT both) (ADJP (JJ positive) (CC and) (JJ negative)) (NN MRI) (NNS cases))))))) (. .))
(S (NP (DT The) (CD 116) (JJ positive) (NN MRI) (NNS scans)) (VP (VBD were) (VP (VBN annotated) (PP (IN by) (NP (NP (NNS radiologists)) (, ,) (VP (VBN confirmed) (PP (IN with) (NP (JJ post-surgical) (NML (JJ whole) (HYPH -) (NN gland)) (NNS specimens)))))))) (. .))
(S (NP (DT The) (NN suspiciousness) (NN map)) (VP (VBD was) (VP (VBN evaluated) (PP (IN by) (NP (NN receiver) (NN operating) (NN characteristic) (-LRB- -LRB-) (NNP ROC) (-RRB- -RRB-) (NN analysis))) (PP (IN for) (NP (NP (NN PCa) (NNS lesions)) (CC versus) (NP (JJ non-PCa) (NML (NML (NNS regions) (NN classification)) (CC and) (NML (JJ free) (HYPH -) (NN response))) (NN receiver)))) (S (VP (VBG operating) (NP (JJ characteristic) (-LRB- -LRB-) (NN FROC) (-RRB- -RRB-) (NN analysis)) (PP (IN for) (NP (NN PCa) (NN localization))))))) (. .))
(S (NP (PRP$ Our) (JJ proposed) (NN method)) (VP (VBD achieved) (NP (CD 0.84) (NN area)) (PP (IN under) (NP (NP (DT the) (NNP ROC) (NN curve)) (CC and) (NP (NML (CD 77.0) (NN %)) (NN sensitivity)))) (PP (IN at) (NP (NP (NP (CD one)) (ADJP (JJ false) (JJ positive))) (PP (IN per) (NP (NP (NN patient)) (PP (IN in) (NP (NN FROC) (NN analysis)))))))) (. .))
